VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 203 filers reported holding VANDA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,174 | -3.6% | 10,228 | +47.0% | 0.00% | – |
| Q2 2023 | $45,833 | +6.0% | 6,957 | +9.3% | 0.00% | – |
| Q1 2023 | $43,221 | +35.1% | 6,367 | +43.6% | 0.00% | – |
| Q4 2022 | $32,000 | -31.9% | 4,435 | -7.7% | 0.00% | – |
| Q3 2022 | $47,000 | -21.7% | 4,805 | -13.2% | 0.00% | – |
| Q2 2022 | $60,000 | -3.2% | 5,535 | +3.0% | 0.00% | – |
| Q1 2022 | $62,000 | -20.5% | 5,373 | +8.7% | 0.00% | – |
| Q4 2021 | $78,000 | +5.4% | 4,944 | +13.1% | 0.00% | – |
| Q3 2021 | $74,000 | -20.4% | 4,372 | +0.7% | 0.00% | – |
| Q2 2021 | $93,000 | +60.3% | 4,342 | +13.7% | 0.00% | – |
| Q1 2021 | $58,000 | +31.8% | 3,819 | +13.9% | 0.00% | – |
| Q4 2020 | $44,000 | +51.7% | 3,352 | +23.0% | 0.00% | – |
| Q3 2020 | $29,000 | -32.6% | 2,726 | -27.0% | 0.00% | – |
| Q2 2020 | $43,000 | +53.6% | 3,732 | +43.0% | 0.00% | – |
| Q1 2020 | $28,000 | – | 2,610 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |